Stocktoria
IMMUNIC, INC. IMUX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-04-17
IMMUNIC, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $82.0M | $80.0M | $83.2M | $71.3M | $61.1M |
| Operating income | -$103.2M | -$98.1M | -$99.2M | -$119.5M | -$91.7M |
| Income tax | $0 | — | — | — | — |
| Net income | -$97.2M | -$100.5M | -$93.6M | -$120.4M | -$92.9M |
| EPS (diluted) | $-0.62 | $-1.00 | $-2.11 | $-3.78 | $-3.93 |
| Operating cash flow | -$85.8M | -$84.8M | -$70.8M | -$65.1M | -$83.2M |
| Free cash flow | -$86.0M | -$85.0M | -$71.2M | -$65.3M | -$83.3M |
| Cash & equivalents | $15.5M | $35.7M | $46.7M | $106.7M | $86.9M |
| Total assets | $24.1M | $40.9M | $54.3M | $127.8M | $139.1M |
| Total liabilities | $30.7M | $22.4M | $25.4M | $14.1M | $12.0M |
| Shareholders' equity | -$6.7M | $18.4M | $28.9M | $113.7M | $127.1M |
Source: SEC EDGAR filings · CIK 0001280776 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.